Prof. Hiroaki Nagano

Osaka University, Japan

Email: hnagano@gesurg.med.osaka-u.ac.jp

Qualifications

1994 Ph.D., Graduate School of Medicine, Osaka University, Japan

1986 M.D., Okayama University Medical School, Japan

Publications (selected)

1. Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y, Mori M. Long-term outcome of combined subcutaneous interferon-a and intra-arterial 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011; 80(1-2): 63-69.
2. Murakami M, Kobayashi S, Marubashi S, Tomimaru Y, Noda T, Wada H, Eguchi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Tyrosine kinase inhibitor PTK/ZK enhances the anti-tumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011; 18(2): 589-596.
3. Noda T, Nagano H, Tomimaru Y, Murakami M, Wada H, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Kim T, Wakasa K, Doki Y, Mori M Prognosis of hepatocellular carcinoma with biliary tumor thrombi following liver surgery. Surgery 2011; 149(3): 371-377.
4. Kobayashi S, Nagano H, Marubashi S, Wada H, Eguchi H, Tanemura M, Sekimoto M, Umeshita K, Doki Y, Mori M. Experience with the use of fibrin sealant plus polyglycolic acid felt at the cut surface of the liver in laparoscopic hepatectomy. Surg Endosc. 2011 Nov; 25(11): 3590-3596..
5. Kobayashi S, Nagano H, Marubashi S, Wada H, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Treatment of borderline cases for curative resection of biliary tract cancer. J Surg Oncol. 2011; 104(5): 499-503.
6. Marubashi S, Nagano H, Wada H, Kobayashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma. Ann Surg Oncol. 2011;18(8):2200-2209.
7. Akita H, Takeda Y, Hoshino H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Mori M, Doki Y, Nagano H Mural Nodule in Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas is a Marker of Malignant Transformation and Indication for Surgery. Am J Surgery 2011; 202(2): 214-219.
8. Akita H, Nagano H, Takeda Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Takahashi H, Ohigashi H, Tomita Y, Ishikawa H, Mori N, Doki Y. EpCAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene 2011; 30(31): 3468-3476.
9. Miyoshi N, Ishii H, Nagano H, Haraguchi N, Dewi DL, Kano Y, Nishikawa S, Tanemura M, Mimori K, Tanaka F, Saito T, Nishimura J, Takemasa I, Mizushima T, Ikeda M, Yamamoto H, Sekimoto M, Doki Y, Mori M. Reprogramming of Mouse and Human Cells to Pluripotency Using Mature MicroRNAs. Cell Stem Cell. 2011; 8(6): 633-638.
10. Tomimaru Y, Eguchi H, Wada H, Noda H, Murakami M, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M, Nagano H. Insulin-Like Growth Factor-Binding Protein 7 Alters the Sensitivity to Interferon-Based Anticancer Therapy in Hepatocellular Carcinoma Cells. B J Cancer 2010;102(10):1483-1490.
11. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, Umeshita K, Matsuura N, Matsubara K, Doki Y, Mori M, Monden M. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009; 100(10): 1647-1658.
12. Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, Dono K, Umeshita K, Sakon M, Monden M. Interferon-α and 5-fluorouracil combination therapy following palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk and multiple nodules. Cancer. 2007;110(11): 2493-2501.
13. Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol. 2007;46(1):77-88.
14. Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007; 141(2): 196-202.
15. Kondo M, Nagano H, Wada H, Damdinsuren B, Yamamoto H, Hiraoka N, Eguchi H, Miyamoto A, Yamamoto T, Ota H, Nakamura M, Marubashi S, Dono K, Umeshita K, Nakamori S, Sakon M, Monden M.Combination of interferon alpha and 5-fluorouracil induces apoptosis through interferon alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res. 2005; 11(3): 1277-1286.
16. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer. 2005; 93(5): 557-564.
17. Ogawa M, Yamamoto H, Nagano H, Miyake Y, Sugita Y, Hata T, Kim BN, Ngan CY, Damdinsuren B, Ikenaga M, Ikeda M, Ohue M, Nakamori S, Sekimoto M, Sakon M, Matsuura N, Monden M. Hepatic expression of ANG2 RNA in metastatic colorectal cancer. Hepatology. 2004; 39(2): 528-539.
18. Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, Miyamoto A, Kondo M, Arai I, Yamamoto T, Ota H, Dono K, Umeshita K, Nakamori S, Sasaki Y, Ishikawa O, Imaoka S, Monden M.Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss ofheterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol. 2003; 39(2): 215-221.
19. Nagano H, Libby P, Taylor MK, Hasegawa S, Stinn JL, Tilney NL, Mitchell RN. Coronary arteriosclerosis after T cell mediated injury in transplanted mouse hearts: role of interferon-gamma. Am J Pathol. 1998; 152(5): 1187-1197.
20. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in thetransplanted mouse heart. J Clin Invest. 1997; 100(3): 550-557.
21. Nagano H, Monden M, Gotoh M, Tanigawa T, Tono T, Nakano Y, Mori T. Induction of unresponsiveness in rats after either intraportal injection of donor antigen or intravenous injection combined with splenectomy. Transplantation. 1993; 56(6): 1468-1472.